急性肾损伤 中国就医指南

Acute Kidney Injury (AKI) is a sudden, often reversible decline in kidney function characterized by an abrupt increase in serum creatinine, decrease in urine output, or both—typically occurring within hours to days. It reflects a spectrum of renal dysfunction ranging from mild tubular injury to severe cortical necrosis and is classified into three stages (Stage 1–3) per the KDIGO (Kidney Disease: Improving Global Outcomes) criteria based on magnitude of creatinine rise and/or urine volume reduction. Pathogenically, AKI arises from three broad mechanisms: prerenal (e.g., hypovolemia, heart failure, sepsis-induced hypoperfusion), intrinsic renal (e.g., acute tubular necrosis from ischemia or nephrotoxins like contrast media, aminoglycosides, NSAIDs, or glomerulonephritis), and postrenal (e.g., urinary tract obstruction from stones, tumors, or prostatic hypertrophy). Cellular injury triggers inflammatory cascades, mitochondrial dysfunction, endothelial activation, and microvascular congestion—culminating in impaired glomerular filtration and tubular transport. Epidemiologically, AKI affects approximately 10–15% of all hospitalized patients globally, with incidence soaring to 30–50% in intensive care units. In China, population-based studies estimate an annual incidence of 2,800–4,200 cases per million adults, disproportionately impacting older adults (>65 years), those with preexisting chronic kidney disease (CKD), diabetes, hypertension, or cardiovascular disease. Key modifiable risk factors include dehydration, uncontrolled sepsis, inappropriate use of nephrotoxic medications, major surgery (especially cardiac and orthopedic), radiocontrast exposure, and delayed recognition of early signs. Non-modifiable risks include advanced age, female sex (in some cohorts), and genetic susceptibility variants (e.g., APOL1 in high-risk populations). Beyond mortality—where Stage 3 AKI carries up to 50% in-hospital death risk—AKI profoundly impairs quality of life: survivors frequently experience persistent fatigue, cognitive slowing, depression, reduced physical endurance, and diminished return-to-work rates. Up to 40% develop new-onset or accelerated CKD within one year, increasing long-term cardiovascular morbidity and dialysis dependence. Early detection via serial creatinine monitoring and urine output tracking remains critical; biomarkers like NGAL and TIMP-2•IGFBP7 show promise for preclinical prediction but are not yet routine in standard practice. Multidisciplinary management—including nephrology consultation within 24 hours of diagnosis—is associated with significantly improved outcomes, underscoring the vital role of dedicated renal medicine services.

# 急性肾损伤（AKI）治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：AKI 1期或2期、病因可逆（如脱水、药物肾毒性、轻度感染）、GFR >30 mL/min/1.73m²、无严重电解质紊乱或容量超负荷。

• •基础支持：液体管理、停用肾毒性药、营养支持（800–1,200元/周）
• •药物治疗：利尿剂（呋塞米注射液，20–60元/支）、碳酸氢钠纠酸（15–35元/支）、钙剂/胰岛素葡萄糖降钾（40–120元/次）
• •检验检查费：血肌酐+电解质+尿常规+NGAL/uCysC（320–480元/次）、肾脏超声（260–380元）

二、肾脏替代治疗（RRT）介入方案

适用人群：AKI 3期、高钾血症（K⁺≥6.0 mmol/L）、严重酸中毒（pH≤7.15）、容量过负荷或尿毒症症状。

• •连续性RRT（CRRT）：体外循环+置换液，含管路耗材、抗凝监测；12,000–18,000元/日（含机器使用、护理、血气/电解质监测）
• •间歇性血液透析（IHD）：3次/周，含透析器、肝素、透析液；850–1,300元/次
• •术前检查：凝血功能+血型+乙肝丙艾滋梅毒+中心静脉置管评估（980–1,450元）

三、特殊复杂情况处理

• •合并脓毒症AKI：加用血浆置换+广谱抗生素（每日额外2,500–4,200元）
• •药物难治性高钾/心律失常：静脉钙剂+聚苯乙烯磺酸钠+新型钾结合剂（环硅酸锆钠，1,980元/盒，疗程3–5天）
• •多器官衰竭需联合支持：CRRT+ECMO协同治疗，25,000–38,000元/日

四、方案快速选择指南

• •预算有限/早期AKI：首选保守治疗+动态监测（单次总费用≤2,000元）
• •中等预算/进展期AKI：IHD起始，兼顾疗效与成本（首周约6,000–9,000元）
• •危重症/多脏器受累：立即启动CRRT（首日投入≥12,000元，但显著降低死亡率）